. "4.9. P\u0159ed\u00E1vkov\u00E1n\u00ED"@cs . "004.009" . "Bylo zaznamen\u00E1no n\u011Bkolik p\u0159\u00EDpad\u016F p\u0159ed\u00E1vkov\u00E1n\u00ED p\u0159\u00EDpravkem Copaxone (do d\u00E1vky 80 mg glatiramer acet\u00E1tu). Tyto p\u0159\u00EDpady nebyly spojeny s jin\u00FDmi ne\u017E\u00E1douc\u00EDmi \u00FA\u010Dinky ne\u017E t\u011Bmi, kter\u00E9 jsou uvedeny v\u00A0bod\u011B 4.8.\nS\u00A0d\u00E1vkami vy\u0161\u0161\u00EDmi ne\u017E 80 mg glatiramer acet\u00E1tu nejsou klinick\u00E9 zku\u0161enosti.\nV\u00A0klinick\u00FDch studi\u00EDch nebyly denn\u00ED d\u00E1vky a\u017E do v\u00FD\u0161e 30 mg glatiramer acet\u00E1tu po dobu a\u017E 24 m\u011Bs\u00EDc\u016F prov\u00E1zeny jin\u00FDmi ne\u017E\u00E1douc\u00EDmi \u00FA\u010Dinky ne\u017E t\u011Bmi, kter\u00E9 jsou uvedeny v\u00A0bod\u011B 4.8.\nV\u00A0p\u0159\u00EDpad\u011B p\u0159ed\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt pacient monitorov\u00E1n a mus\u00ED b\u00FDt zah\u00E1jena odpov\u00EDdaj\u00EDc\u00ED symptomatick\u00E1 a podp\u016Frn\u00E1 l\u00E9\u010Dba.\n"@cs . . .